Diligence memo · auto-generated · as of July 2, 2026

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Pasithea Therapeutics Corp. operates in Pharma, based in MIAMI BEACH.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pasithea Therapeutics Corp. has raised $32M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $30M on 2021-11-29.

Most recent recorded round closed around 2021-11-29.

Valuation (modeled)modeled

Provath models Pasithea Therapeutics Corp. at approximately $591M (range $64M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.82× the median modeled value of Series B Pharma companies in 2019–2021 (8 peers) — value vs value, same stage and era. Within the normal band (82% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 4.6 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 25.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 82% of Pharma peers (310 compared).

Modeled value ranks above 87% of those peers.

Closest niche peers: Skincure Oncology Llc, Rescale, Inc., Small Pharma Financing Inc., Oncology Analytics, Inc., Kwivik Therapeutics, Inc..

Peoplefiled

10 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.